PositiveIDs ExcitePCR Subsidiary to Hold Press Conference
Announcing Lawrence Livermore National Report on its FireflyDX
Press Conference to be Held on September 18th at the National
Press Club in Washington, D.C.
DELRAY BEACH, FL September 12, 2017, InvestorsHub NewsWire
-- PositiveID Corporations (OTCQB: PSID) ExcitePCR subsidiary today announced that it will hold
a Press Conference at 10 a.m. on Monday, September 18th at the
National Press Club in Washington, D.C., to disclose details from a
new report produced by Lawrence Livermore National Laboratory for
ExcitePCR on the FireflyDX pathogen detection system.
During the Press Conference, ExcitePCR will summarize its
multiyear history in designing, developing and producing automated
biohazard detection for U.S. governmental agencies and military
organizations, as well as showcase its forthcoming
FireflyDX-Portable pathogen detection system and select details
from the report produced by LLNL for the company.
WHAT:
An ExcitePCR Press Conference on Monday, September 18, 2017,
from 10-11 a.m. (ET) will disclose details from a Lawrence
Livermore National Laboratory Report prepared for the company that
states that ExcitePCRs FireflyDX automated pathogen detection
technologies have no known direct competition. {NOTE: ExcitePCR
will release its own Executive Summary of the LLNL Report during
the Press Conference.}
During the press conference, ExcitePCR will also provide
additional details about its lightweight, bookbag-sized
FireflyDX-Portable, a realtime pathogen detection system designed
to enable first responders, medical professionals and food safety
workers to accurately obtain on-site results anywhere in the world
in less than 30 minutes, including sample preparation time.
WHERE:
The ExcitePCR Press Conference will be held at the National
Press Club in Washington, D.C. at 529 14th Street NW, Washington,
D.C.
WHEN:
The ExcitePCR Press Conference will be held from 10-11 a.m. (ET)
on Monday, September 18, 2017.
WHO:
Representing ExcitePCR at the press conference will be
Lyle Probst, President, CEO, and Founder;
Kimothy Smith, Ph.D., Chief Science Officer; and
David Politis, Chief Marketing & Sales Officer.
JOURNALISTS & ANALYSTS WHO SHOULD ATTEND:
Journalists and Analysts interested in and/or who cover/report
on infectious diseases, pandemics, epidemics, biohazards,
pathogenic threats, First Responders, Homeland Security, the
military, and/or Polymerase Chain Reaction (PCR), as well as those
who follow or have reported on such firms as Theranos, bioMerieux,
Thermo Fisher Scientific, are those most likely to appreciate the
information that will be shared during ExcitePCRs September 18th
Press Conference.
WHY:
Including its predecessor companies, ExcitePCR has received over
$35 million since 2004 from the U.S. Department of Homeland
Security (DHS) and other U.S. governmental entities to design,
develop and produce rapid pathogen detection solutions. This
foundational work has allowed ExcitePCR to produce significant
breakthroughs in the world of PCR-based solutions for rapidly and
accurately identifying the presence of countless biological threats
anywhere in the world, including the typically time-consuming act
of sample preparation, all within 30 minutes or less. ExcitePCR has
now begun work to commercialize its FireflyDX technologies that
Lawrence Livermore National Laboratory says have no known
competition.
ADDITIONAL INFORMATION:
Following the Press Conference, ExcitePCRs CEO, Lyle Probst,
will participate in a prestigious, three-person Panel Discussion
about current and future advancements in pathogen detection systems
hosted by the National Academies of Science,
Engineering, and Medicine (NAS). This panel discussion part of
a two-day, BioWatch Workshop on Strategies for Effective Biological
Detection Systems hosted by the NAS. Interested parties can learn
more about this Panel Discussion here.
About PositiveID Corporation
PositiveID Corporation is a holding company focused on life
sciences, diagnostics, mobile laboratories, and medical devices.
PositiveIDs ExcitePCR subsidiary is developing the FireflyDX
family of pathogen detection systems, portable devices offering
rapid sample-to-result detection in less than 30 minutes using
real-time polymerase chain reaction chemistry. PositiveIDs E-N-G Mobile
Systems subsidiary is a leader in the mobile technology vehicle
market, with a focus on the laboratory market and homeland
security. PositiveIDs Thermomedics subsidiary markets the
FDA-cleared Caregiver non-contact thermometer for clinical use. For
more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on
Twitter, Facebook or LinkedIn.
On August 24, 2017, PositiveID Corporation and its wholly-owned
subsidiary PositiveID Diagnostics, Inc. (collectively, the Seller),
entered into an Asset Purchase Agreement (APA) with ExcitePCR
Corporation. Pursuant to the APA, at closing, the Seller will sell
and deliver to ExcitePCR all assets used in connection with the
operation of the FireflyDX technology. For more information on the
APA, please read PositiveIDs Form 8-K filed on August 28, 2017,
which can be found here.
Disclaimer: This document may contain research results that are
experimental in nature, and neither the United States Government,
any agency thereof, Lawrence Livermore National Security, LLC, nor
any of its employees makes any warranty, express or implied, or
assumes any legal liability or responsibility for the accuracy,
completeness, or usefulness of any information, apparatus, product,
or process disclosed, or represents that its use would not infringe
privately owned rights. Reference to any specific commercial
product, process, or service by trade name, trademark,
manufacturer, or otherwise does not constitute or imply an
endorsement or recommendation by the U.S. Government or Lawrence
Livermore National Security, LLC. The views and opinions of authors
expressed herein do not necessarily reflect those of the U.S.
Government or Lawrence Livermore National Security, LLC and will
not be used for advertising or product endorsement purposes.
Statements about PositiveID's future expectations, including the
likelihood that ExcitePCR has begun work to commercialize its
FireflyDX technologies that Lawrence Livermore National Laboratory
says have no known competition; the likelihood that
FireflyDX-Portable is a realtime pathogen detection system designed
to enable first responders, medical professionals and food safety
officials to accurately obtain on-site results anywhere in the
world in less than 30 minutes, including sample preparation time;
the likelihood that pursuant to the APA, at closing, the Seller
will sell and deliver to ExcitePCR all assets used in connection
with the operation of the FireflyDX technology; constitute
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and as that term is defined in the Private Litigation
Reform Act of 1995. Such forward-looking statements involve risks
and uncertainties and are subject to change at any time, and
PositiveID's actual results could differ materially from expected
results. These risks and uncertainties include, without limitation,
ExcitePCRs ability to complete a financing of at least $3 million;
PositiveIDs and ExcitePCRs ability to close the asset purchase
agreement among PositiveID, PositiveID Diagnostics, and ExcitePCR;
PositiveIDs ability to attract new customers and partners;
PositiveIDs ability to raise capital; ExcitePCRs ability to
complete the development and commercialization of the
FireflyDX-Portable and FireflyDX-Handheld; as well as other risks.
Additional information about these and other factors that could
affect the Company's business is set forth in the Company's various
filings with the Securities and Exchange Commission, including
those set forth in the Company's 10-K filed on March 31, 2017, and
10-Qs filed on August 14, 2017, May 15, 2017, and November 18,
2016, under the caption "Risk Factors." The Company undertakes no
obligation to update or release any revisions to these
forward-looking statements to reflect events or circumstances after
the date of this statement or to reflect the occurrence of
unanticipated events, except as required by law.
Contacts:
PositiveID Corporation
Allison Tomek
(561) 805-8044
atomek@psidcorp.com